Technical Analysis for DMAC - DiaMedica Therapeutics Inc.
Grade | Last Price | % Change | Price Change |
---|---|---|---|
B | 3.47 | -5.19% | -0.19 |
DMAC closed down 5.19 percent on Wednesday, May 8, 2024, on 2.3 times normal volume. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or a pulls back.
Earnings due: May 9
*** please verify all earnings dates ***ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Up | Up | Up |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Stochastic Sell Signal | Bearish | 0.00% | |
Slingshot Bullish | Bullish Swing Setup | 0.00% | |
Wide Range Bar | Range Expansion | 0.00% | |
Upper Bollinger Band Walk | Strength | 0.00% | |
Wide Bands | Range Expansion | 0.00% | |
Above Upper BB | Strength | 0.00% | |
Overbought Stochastic | Strength | 0.00% | |
Upper Bollinger Band Touch | Strength | 0.00% | |
Pocket Pivot | Bullish Swing Setup | -5.19% | |
Volume Surge | Other | -5.19% |
Alert | Time |
---|---|
2x Volume Pace | about 20 hours ago |
Down 10% | about 20 hours ago |
Down 2 ATRs | about 20 hours ago |
60 Minute Opening Range Breakdown | about 21 hours ago |
Gapped Down (Full) | about 21 hours ago |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/09/2024
DiaMedica Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of treatments for neurological and kidney diseases. The company's lead product is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase II clinical trials for the treatment of acute ischemic stroke and kidney injury indications. It is also developing DM199 for the treatment vascular dementia. In addition, the company is developing DM300, which is in pre-clinical stage for the treatment for acute pancreatitis. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Life Sciences Pharmacy Kidney Disease Stroke Dementia Ischemia Kallikrein Pancreatitis Acute Pancreatitis
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Life Sciences Pharmacy Kidney Disease Stroke Dementia Ischemia Kallikrein Pancreatitis Acute Pancreatitis
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 4.75 |
52 Week Low | 1.58 |
Average Volume | 44,543 |
200-Day Moving Average | 2.77 |
50-Day Moving Average | 2.80 |
20-Day Moving Average | 2.68 |
10-Day Moving Average | 2.91 |
Average True Range | 0.23 |
RSI (14) | 69.23 |
ADX | 20.13 |
+DI | 38.39 |
-DI | 25.86 |
Chandelier Exit (Long, 3 ATRs) | 3.04 |
Chandelier Exit (Short, 3 ATRs) | 2.95 |
Upper Bollinger Bands | 3.45 |
Lower Bollinger Band | 1.91 |
Percent B (%b) | 1.01 |
BandWidth | 57.48 |
MACD Line | 0.16 |
MACD Signal Line | 0.03 |
MACD Histogram | 0.1351 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 4.38 | ||||
Resistance 3 (R3) | 4.33 | 3.98 | 4.22 | ||
Resistance 2 (R2) | 3.98 | 3.75 | 4.00 | 4.17 | |
Resistance 1 (R1) | 3.72 | 3.60 | 3.55 | 3.77 | 4.12 |
Pivot Point | 3.37 | 3.37 | 3.29 | 3.40 | 3.37 |
Support 1 (S1) | 3.12 | 3.14 | 2.95 | 3.17 | 2.82 |
Support 2 (S2) | 2.77 | 3.00 | 2.79 | 2.77 | |
Support 3 (S3) | 2.52 | 2.77 | 2.72 | ||
Support 4 (S4) | 2.56 |